Risk thresholds for patients to switch between daily tablets and biweekly infusions in second-line treatment for advanced hepatocellular carcinoma: a patient preference study

Peer Review reports

Original Submission
4 Mar 2022	Submitted	Original manuscript
Resubmission - Version 2
	Submitted	Manuscript version 2
Resubmission - Version 3
	Submitted	Manuscript version 3
23 Apr 2022	Reviewed	Reviewer Report - Takeshi Terashima
2 Aug 2022	Reviewed	Reviewer Report
30 Aug 2022	Author responded	Author comments - Marco Boeri
Resubmission - Version 4
30 Aug 2022	Submitted	Manuscript version 4
Publishing
30 Nov 2022	Editorially accepted
19 Jan 2023	Article published	10.1186/s12885-022-10388-8

Back to article page